We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nextgen | NGG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 78.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 78.00 | 78.00 |
| Top Posts |
|---|
Posted at 02/10/2012 13:17 by the_doctor Hopefully not to many listened to the clueless rampers here like Stephanie MCrazy how much the managers were paying themselves in the run up to NGG going bust! The FSA should ban them from further roles for encouraging paid broker notes just before suspending and winding down the company Bad luck folk who invested I suspect the directors will now pick up the pieces for nothing with one of the major shareholders' backing instead? |
Posted at 30/4/2012 16:03 by gammelgaard With a positive attitude one can get very far - thats my experience. And NGG is surely an interesting company, not to mention its products. Wait and see! |
Posted at 30/4/2012 14:09 by andrbea ngg 10%30/04/2012 15:06:15 NGG 0.20 O 2,600,000 30/04/2012 15:06:11 NGG 0.20 O 2,600,000 30/04/2012 12:12:38 NGG 0.15 O 1,700,000 30/04/2012 12:12:13 NGG 0.15 O 1,700,000 30/04/2012 11:10:07 NGG 0.14 O 275,000 |
Posted at 20/3/2012 16:12 by stephanie_m Increased interest in NGGs |
Posted at 13/3/2012 09:37 by stephanie_m UK-Analyst: featuring,Gulf Keystone, Close Brothers and NextGen Group Today (2012-03-13 17:26:55)"Staying on the topic of disease treatment, NextGen Group (NGG) announced it has filed for intellectual property on a combination of protein biomarkers which have the potential to diagnose cognitive changes in patients with early-stage dementia. The firm believes the product will have a duel purpose, to identify the progression of the disease in patients, but also to aid drug companies in the patient selection process for clinical trials. With more than 36 million people suffering from the disease globally, and almost 500 dementia and cognitive clinical trials currently in progress, the firm believes it is now in a strong position to exploit a huge market. NextGen shares surged 0.025p to 0.225p." s |
Posted at 13/3/2012 07:26 by stephanie_m Tuesday 13 March, 2012NextGen Group PLC IP Filings RNS Number : 2069Z NextGen Group PLC 13 March 2012 March 13 2012 Issued by NextGen Group Plc NextGen files for intellectual property on dementia biomarkers · Intention to pursue IP across multiple dementia areas · Further studies planned to expand patent portfolio NextGen Group Plc (AIM: NGG), an AIM listed company providing biomarker discovery services and diagnostic assay development, announces that its subsidiary, NextGen Sciences Dx (NGSDx), has filed for intellectual property (IP) on a combination of protein biomarkers with the potential for diagnosing changes in cognition for patients with early-stage dementia. Barry McAleer, PhD, CEO of NextGen Sciences Inc and NextGen Sciences Dx, says: "The biomarkers we have identified in cerebrospinal fluid (CSF) have the potential to aid decision-making on how to treat patients who have early-stage dementia (i.e. mild-moderate cognitive impairment), to assist in patient selection for clinical trials and to monitor the effectiveness of drugs in development. It gives us an immediate foothold in a critical healthcare market." |
Posted at 19/1/2012 08:26 by stephanie_m Going to make a further speculative investment in NGG. A takeover perhaps? s |
Posted at 22/6/2011 10:48 by the_doctor NMJ2, what I suggested was naive were your comments in 257 that have nothing to do with whether NGG will make moneyYou've still not explained why NGG's assays will make much. 'but for the life of me i can,t see why your here' I'm here to pass on learnings from other company's assays to suggest that people think carefully about how much the assays will earn. Not you, but there are some vicious rampers that jumped on the 'biospike' bandwagon. |
Posted at 21/6/2011 06:47 by lady gaga .5p anyone lolHome Log In Register Our Services My Account Contact Help Stockwatch Level 2 Portfolio Charts Shares Magazine Research Share Price Indices Market Scan Company Zone Traders' Room NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News iPhone Forex Director Deals Investors' Room Credit Cards A-Z of Brokers Directory Bookshop Awards 2011 Mortgages ISAs PLUS Simply Chart Broker Notes Forward Diary You are NOT currently logged in . Keyword Company EPIC/TIDM SEDOL/ISIN Tuesday 21 June, 2011 NextGen Group PLC New Assay Launch RNS Number : 7769I NextGen Group PLC 21 June 2011 NextGen Group Plc NextGen Sciences launches multiple protein cerebrospinal fluid (CSF) CNS disease biomarker assay London, UK and Ann Arbor, Michigan, US, 21 June 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification. The assay simultaneously measures 43 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer's, Parkinson's, multiple sclerosis and ALS diseases. The launch of csfdiscovery43 is the next step in NextGen Sciences strategy of becoming a leading player in the growing CNS and oncology biomarker markets. NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform, and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. In addition to the CNS disease focus, the assay can be used for early-stage biomarker discovery and qualification in other disease areas e.g. traumatic brain injury (TBI). NextGen expects to continue to add proteins to the csfdiscovery43 assay, in addition to developing other disease-focused assay panels, both as proprietary products and with other companies through partnerships and collaborations. Klaus Rosenau, Chairman and CEO of NextGen Group, commented, 'The release of csfdiscovery43 is the next defining step in the development of NextGen Sciences' biomarker business, following its reorganization and release of the plasmadiscovery41 assay in Q1. It demonstrates that we have once again delivered on our plans to develop multiplex protein assays that will help to establish the company as a market leader in biomarker discovery and qualification using its MRM technology. Importantly, this enables us to further target increasing market share from the $600m mass spectrometry based biomarker discovery market. We believe that pharmaceutical, biotechnology and diagnostics companies need high-quality assays relevant to their disease areas to inform their decision-making processes, and NextGen Sciences is currently working on the launch of more such products.' - ENDS - For more information please contact : NextGen Group Klaus Rosenau, Chairman and CEO klaus.rosenau@nextge +49 160 551 6756 Seymour Pierce Jonathan Wright, Nicola Marrin +44 (0) 20 7107 8000 Notes to Editors NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarket This information is provided by RNS The company news service from the London Stock Exchange END MSCSESFMSFFSEFM Investegate takes no responsibility for the accuracy of the information within the site. The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site. -------------------- © 2011 Financial Express. All rights reserved. Stockwatch Level 2 Portfolio Charts Shares Magazine Research Share Price Indices Market Scan Company Zone Traders' Room NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News iPhone Forex Director Deals Investors' Room Credit Cards A-Z of Brokers Directory Bookshop Awards 2011 Mortgages ISAs PLUS Simply Chart Broker Notes Forward Diary About an ADVFN competitor Ts and Cs Privacy Policy Investment Warning Content Standards Corporate Solutions Advertise With Us Site Map © 2011 an ADVFN competitor Register now for FREE Share Prices, Stock Quotes, Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research or see our Premium Services including Level 2, Terminal and much more. Follow us on Twitter |
Posted at 19/3/2011 09:28 by loveabul What do people think of the late RNS friday.Is it good or bad news. Regulatory Story Go to market news section Company NextGen Group PLC TIDM NGG Headline Grant of Options Released 17:04 18-Mar-2011 Number 2618D17 RNS Number : 2618D NextGen Group PLC 18 March 2011 NextGen Group plc (the "Company") Grant of Options Ann Arbor, Michigan, US, and London, UK, 18 March 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that on 18 March 2011 it approved an option plan totaling 2,584,014,751 options for management and employees of NGG and Next Gen Sciences Inc. (NGS) in the UK and the US. NextGen Sciences Inc., which is a subsidiary of NextGen Group, is a leader in biomarker discovery, measurement and qualification. The scheme has been created as an incentive stock option plan with clear near-term and long-term goals to be attained by management and employees for the options to vest, and represents an important part of the company's new biomarker business strategy. Approximately 30% of the total option plan (667,374,336 unissued shares currently authorized for allotment) vest pro rata to each option holder on 18 March 2011 and the remaining options will vest later and will be exercisable subject to satisfaction of objective criteria such as total profitability, sales and biomarker assay development. This remainder of the option plan will be issued and granted after approval at NGG'S AGM, expected to be held at the end of April this year. The options have an exercise price of 0.1p except for US employees where, for tax reasons, the exercise price has been set as the VWAP of shares in the Company for the 30 days prior to board approval, that is 0.33p., All options have to be exercised before 18 March 2021 whereafter they will lapse. The total option plan corresponds to 19.8% of the current fully diluted share capital. The total number of options held following this grant is set out below: Total holding as at 18 March 2011 Management and Board Klaus Rosenau, Chairman & CEO, NGG 273,685,139 Leif Hamø, CFO, NGG 117,293,631 Barry McAleer, CEO, NGS 117,293,631 Thomas Borcholte, non-executive director, NGG 10,500,000 Company Secretary Thomas Przygoda 15,000,000 Other employees UK employees 14,911,131 US employees 60,150,000 Other OAR GmbH1 33,715,804 Total 642,549,336 1 OAR GmbH is a German consultancy company that is doing consultancy work for NextGen Group. None of the above people or entities have options before this grant. Furthermore it has been agreed that NextGen Group Plc will pay its broker Dowgate Capital Stockbrokers Limited for services provided in 2010 and the first half of 2011 in shares in the Company, such shares to be issued at a price of 0.3p for 2,400,000 shares. Accordingly, application will be made for a total of 2,400,000 ordinary shares to be admitted to trading on AIM and trading is expected to commence on 24 March 2011. - ENDS - For more information please contact : NextGen Group Plc. Klaus Rosenau, Chairman and CEO klaus.rosenau@nextge +49 160 551 6756 Seymour Pierce Jonathan Wright, Nicola Marrin +44 (0) 20 7107 8000 Notes to Editors NextGen Sciences Inc. (Ann Arbor, MI, USA) is the subsidiary of NextGen Group Plc., London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalised medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarket This information is provided by RNS The company news service from the London Stock Exchange END RDSSFDFWAFFSESD London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. ©2009 London Stock Exchange plc. All rights reserved Regulatory |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
